351,408 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Penn Capital Management Company LLC

Penn Capital Management Company LLC purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 351,408 shares of the biopharmaceutical company's stock, valued at approximately $10,577,000. Penn Capital Management Company LLC owned approximately 0.23% of TG Therapeutics as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TGTX. Clearbridge Investments LLC purchased a new stake in TG Therapeutics in the 4th quarter worth approximately $55,237,000. Principal Financial Group Inc. raised its position in shares of TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares during the period. Raymond James Financial Inc. purchased a new position in shares of TG Therapeutics during the 4th quarter valued at $14,508,000. Braun Stacey Associates Inc. purchased a new stake in TG Therapeutics in the 4th quarter worth $13,328,000. Finally, Norges Bank purchased a new position in shares of TG Therapeutics in the fourth quarter valued at about $12,085,000. Institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX traded up $1.12 during midday trading on Tuesday, reaching $43.15. 997,016 shares of the stock traded hands, compared to its average volume of 2,674,614. The company's 50 day moving average is $37.40 and its 200 day moving average is $32.73. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $43.32. The stock has a market capitalization of $6.85 billion, a PE ratio of -431.49 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.